Real‐world effectiveness of Azvudine versus nirmatrelvir‐ritonavir in hospitalized patients with COVID‐19

Journal of Medical VirologyVolume 95, Issue 6 e28836 LETTER TO THE EDITOR Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 Guangting Zeng, Corresponding Author Guangting Zeng [email protected] orcid.org/0000-0001-6844-3949 Department of Pharmacy, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China Correspondence Guangting Zeng, Department of Pharmacy, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China. Email: [email protected]Search for more papers by this authorLinlin Wang, Linlin Wang Department of Pharmacy, Cancer Center(Xiamen), Fudan University, Xiamen, ChinaSearch for more papers by this authorJianqiang Li, Jianqiang Li Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaSearch for more papers by this authorZanling Zhang, Zanling Zhang Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaSearch for more papers by this author Guangting Zeng, Corresponding Author Guangting Zeng [email protected] orcid.org/0000-0001-6844-3949 Department of Pharmacy, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China Correspondence Guangting Zeng, Department of Pharmacy, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China. Email: [email protected]Search for more papers by this authorLinlin Wang, Linlin Wang Department of Pharmacy, Cancer Center(Xiamen), Fudan University, Xiamen, ChinaSearch for more papers by this authorJianqiang Li, Jianqiang Li Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaSearch for more papers by this authorZanling Zhang, Zanling Zhang Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaSearch for more papers by this author First published: 29 May 2023 https://doi.org/10.1002/jmv.28836 Guangting Zeng and Linlin Wang contributed equally. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. REFERENCES 1Deng G, Li D, Sun Y, et al. Real-world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID-19: a retrospective cohort study. J Med Virol. 2023; 95(4):e28756. 2Goldberg Y, Mandel M, Woodbridge Y, et al. Similarity of protection conferred by previous SARS-CoV-2 infection and by BNT162b2 vaccine: a 3-month nationwide experience from Israel. Am J Epidemiol. 2022; 191(8): 1420- 1428. 3Moreira ED, Kitchin N, Xu X, et al. Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine. N Engl J Med. 2022; 386(20): 1910- 1921. 4Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021; 384(8): 693- 704. 5Abraham T, Adcock K, Ahmed N, et al. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet (British edition). 2023; 401(10387): 1499- 1507. 6Salton F, Confalonieri P, Centanni S, et al. Prolonged higher dose methylprednisoloneversus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS). Eur Respir J. 2023; 61(4):2201514. 7Gao Y, Luo Z, Ren S, et al. Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19. J Infect. 2023; 86(6): e158- e160. 8Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ. 2020; 369: m1443. Volume95, Issue6June 2023e28836 ReferencesRelatedInformation